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Summary
 
Cytotoxic T lymphocyte antigen 4 (CTLA4) appears to negatively regulate T cell activation.
One mechanism by which CTLA4 might antagonize T cell function is through inhibition of
CD28 signaling by competing for their shared ligands B7-1 and B7-2. In addition, CTLA4 li-
gation could initiate a signaling cascade that inhibits T cell activation. To address whether
CTLA4 could inhibit immune responses in the absence of CD28, rejection of heart allografts
was studied in CD28-deficient mice. H-2
 
q
 
 hearts were transplanted into allogeneic wild-type
or CD28-deficient mice (H-2
 
b
 
). Graft rejection was delayed in CD28-deficient compared with
wild-type mice. Treatment of wild-type recipients with CTLA4-immunoglobulin (Ig), or with
anti–B7-1 plus anti–B7-2 mAbs significantly prolonged allograft survival. In contrast, treatment
of CD28-deficient mice with CTLA4-Ig, anti–B7-1 plus anti–B7-2 mAbs, or a blocking anti-
CTLA4 mAb induced acceleration of allograft rejection. This increased rate of graft rejection
was associated with more severe mononuclear cell infiltration and enhanced levels of IFN-
 
g
 
and IL-6 transcripts in donor hearts of untreated wild-type and CTLA4-Ig– or anti-CTLA4
mAb–treated CD28-deficient mice. Thus, the negative regulatory role of CTLA4 extends be-
yond its potential ability to prevent CD28 activation through ligand competition. Even in the
absence of CD28, CTLA4 plays an inhibitory role in the regulation of allograft rejection.
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C
 
ytotoxic T lymphocyte antigen 4 (CTLA4) and CD28
are T cell molecules that share sequence homology
and bind to the same ligands, B7-1 (CD80) and B7-2
(CD86). Unlike the constitutively expressed CD28, CTLA4
expression is induced on T lymphocytes by TCR stimula-
tion, and its upregulation in vitro
 
 
 
depends on the presence
of IL-2 and CD28 ligation (1). Furthermore, in contrast to
the costimulatory activity of CD28, CTLA4 appears to
function as a negative regulator of T cell activation (2).
CTLA4 blocking antibodies administered in vivo to wild-
type mice have been reported to increase antitumor (3) and
antiparasite responses (4), to accelerate the onset of diabetes
in TCR transgenic nonobese diabetic mice (NOD mice;
reference 5), and to exacerbate disease in an experimental
allergic encephalomyelitis model (EAE; reference 6). In ad-
dition, CTLA4-deficient mice develop a lymphoprolifera-
tive disease (7, 8), whereas CD28-deficient T cells exhibit
decreased proliferative responses to mitogens (9).
 
The mechanisms underlying the inhibitory activity of
CTLA4 are not clearly understood. It has been proposed
that CTLA4 decreases T cell responses by inhibiting CD28
signaling (10). This may occur either through preferential
binding of CTLA4 to B7-1 and B7-2, as the affinity of
CTLA4 for B7 family members is 
 
z
 
10 times greater than
that of CD28 (11); through competition for common in-
tracellular enzymes (for example, both CD28 [12] and
CTLA4 [13] can bind phosphatidylinositol 3-kinase [PI3-
kinase]); or through the activation of specific molecules
that might directly inhibit CD28 intracellular signaling. An
alternate hypothesis is that CTLA4 may counteract TCR
signals independently of CD28. One way to distinguish these
possibilities is to analyze the role of CTLA4 in T cells from
CD28-deficient mice.
CD28-deficient mice can mount effective immune re-
sponses, including the clearance of viruses (9) and the rejec-
tion of skin grafts (14), albeit less vigorously than wild-type
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mice. This suggests that additional, alternative, or compen-
satory costimulatory mechanisms to CD28 signaling do ex-
ist in vivo. It has been reported previously that CTLA4
does not have any function on T cells from CD28-defi-
cient mice during primary stimulations in vitro (15). How-
ever, we reasoned that chronic stimulation in vivo might
reveal a function for CTLA4 independent of the presence
of CD28 on T cells. To address whether CTLA4 could in-
hibit TCR-driven responses in a CD28-independent man-
ner in vivo, cardiac allografts were transplanted into
CD28
 
1
 
/
 
1
 
 and CD28
 
2
 
/
 
2
 
 mice under conditions in which
CTLA4 binding to B7 family members was prevented.
CTLA4 blockade was found to accelerate the acute rejec-
tion of cardiac allografts in CD28-deficient mice. This
strongly indicates an inhibitory role for CTLA4 that is in-
dependent of its potential effects on CD28.
 
Materials and Methods
 
Mice.
 
CD28-deficient mice were generated as described pre-
viously (9) and back-crossed to C57BL/6 (H-2
 
b
 
) mice for six
generations. CD1 (H-2
 
q
 
) mice were purchased from Charles
River Laboratories (Wilmington, MA), and C57BL/6 mice were
obtained from The Jackson Laboratory (Bar Harbor, ME). Ani-
mals were all housed in a specific pathogen–free facility and used
at 10–14 wk of age. Animals received humane care in compliance
with the Guide for the Care and Use of Laboratory Animals pub-
lished by the National Institutes of Health (Bethesda, MD).
 
Reagents.
 
Human CTLA4-Ig, a fusion protein between the
extracellular domain of human CTLA4 and the Fc portion of hu-
man IgG1, as well as anti–mouse B7-1 and anti–mouse B7-2,
were generated by Genetics Institute. L6, a control human IgG1
had been obtained previously from Repligen Corp. (Needham,
MA). The blocking anti-CTLA4 mAb 4F10 (2) was purchased
from PharMingen (San Diego, CA).
 
Heart Transplantation.
 
C57BL/6 CD28
 
1
 
/
 
1
 
 or CD28
 
2
 
/
 
2
 
 mice
were anesthetized and mechanically ventilated. CD1 donor hearts
were heterotopically transplanted into a cervical location using a
microvascular technique, as described previously (16). Allograft
survival was assessed by daily palpation. Rejection was defined as
cessation of heart beat. Animals were treated with CTLA4-Ig
(200 
 
m
 
g i.p. on day 2 after transplant), anti–B7-1 plus anti–B7-2
(100 
 
m
 
g i.p. each on days 0, 2, and 4), anti-CTLA4 mAb (100 
 
m
 
g
i.p./d for 7 d), or control human IgG1 (200 
 
m
 
g i.p. on day 2).
 
Flow Cytometry.
 
Splenocytes from C57BL/6 CD28
 
1
 
/
 
1
 
 and
CD28
 
2
 
/
 
2
 
 mice (25 
 
3
 
 10
 
6
 
 cells) were incubated in upright flasks
(Costar Corp., Cambridge, MA) for 6 d in the presence of irradi-
ated (2,000 rads) CD1 splenocytes (25 
 
3
 
 10
 
6
 
 cells) in complete
medium supplemented with recombinant human IL-2 (20 U/ml)
to maintain cell viability. Live cells were restimulated with fresh
irradiated CD1 splenocytes (10
 
6
 
 each) and human IL-2 (20 U/ml)
in 24-well plates (Costar Corp.). After 72 h, cells were stained for
surface CD4 and total CTLA4, as described previously (1). Two-
color flow cytometry was performed using a FACScan
 
Ò
 
 flow cy-
tometer (Becton Dickinson, Mountain View, CA). Data analysis
was performed using CellQuest software (Becton Dickinson).
 
Histology.
 
Hearts were harvested and sectioned transversally
at the maximal circumference of the ventricle, fixed in 4% forma-
lin, embedded in paraffin, stained with hematoxylin and eosin,
and analyzed using an optical microscope.
 
RNase Protection Assay.
 
Cardiac grafts harvested at different
 
days after transplantation were quick frozen in dry ice and kept at
 
2
 
80
 
8
 
C until assayed. Frozen hearts were homogenized in 3–5 ml
of Trizol (Life Technologies, Inc., Gaithersburg, MD), and RNA
was extracted according to the manufacturer’s protocol. Samples
were normalized by optical density and by visualizing 18S and
28S RNA on a 1% agarose gel before use. The RNase protection
assay was performed on 5 
 
m
 
g of RNA/sample using a multiprobe
RNase protection assay system (Riboquant; PharMingen). L32
and GAPDH probes were used to assess the total amount of
RNA loaded per lane.
 
Statistical Analysis.
 
Mean cardiac graft survival and SE were
calculated for each group using the Kaplan-Meier estimate. Graft
survival in the different groups was compared using the log–rank
test. Differences were considered to be statistically significant at a
confidence interval of 95% (
 
P
 
 ,
 
0.05).
 
Results
 
Delayed Cardiac Allograft Rejection in CD28-deficient Mice
Compared with that in Wild-type Mice.
 
Hearts from CD1 mice
(H-2
 
q
 
) were transplanted into fully allogeneic C57BL/6
wild-type mice (H-2
 
b
 
). The allografts were promptly re-
jected, as evidenced by cessation of cardiac contraction at 1
wk after transplantation (mean survival 
 
6
 
 SE of 6 
 
6
 
 1 d;
Table 1). In contrast, significant prolongation of cardiac al-
lograft survival was observed in C57BL/6 CD28-deficient
animals (mean survival of 15 
 
6
 
 3 d,
 
 P 
 
,
 
0.001).
 
CD28-deficient Cells Can Upregulate CTLA4 in Response
to Allostimulation.
 
To determine if CTLA4 can be upreg-
ulated in CD28-deficient T cells in response to allogeneic
challenge, splenocytes from C57BL/6 CD28-expressing
and CD28-deficient mice (H-2
 
b
 
) were stimulated in vitro
with irradiated allogeneic CD1 (H-2
 
q
 
) splenocytes for 6 d.
A secondary stimulation was performed for 3 d on the ex-
panded allogeneic-specific surviving cells, and CTLA4 ex-
pression on T cells was assessed by flow cytometry at 72 h.
Both wild-type and CD28-deficient T cells displayed simi-
lar upregulation of CTLA4 in response to an allogeneic
stimulation (Fig. 1). This result was consistent with the
possibility that CTLA4 might affect allogeneic immune re-
sponses in CD28-deficient mice.
 
CTLA4-Ig and Anti–B7-1 plus Anti–B7-2 Exert Opposite Ef-
fects in CD28
 
1
 
/
 
1
 
 and CD28
 
2
 
/
 
2
 
 Mice.
 
To investigate whether
CTLA4 plays a regulatory role in allograft rejection inde-
pendent of CD28, C57BL/6 CD28
 
1
 
/
 
1
 
 and CD28
 
2
 
/
 
2
 
 mice
 
Table 1.
 
Delayed Cardiac Allograft Rejection in
CD28-deficient Mice
 
Cardiac allograft recipient Graft survival
 
d
 
C57BL/6 wild-type 5,6,5,7,5,6,5,6,6,6,6
C57BL/6 CD28-deficient 12,28,11,10,10,38,10,9,9,17,12,11
Wild-type or CD28-deficient mice (H-2
 
b
 
) received a heart allograft
(H-2
 
q
 
). Animals were examined daily; rejection was defined by cessa-
tion of beating of the allograft, and was confirmed by histology. 
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were transplanted with CD1 cardiac allografts and subse-
quently treated with either CTLA4-Ig, or anti–B7-1 plus
anti–B7-2 mAbs. Control animals were left untreated or
received control human IgG1. Mean graft survival of
IgG1-treated animals was similar to that of untreated mice
in both CD28
 
1
 
/
 
1
 
 (mean graft survival 
 
5
 
 6 
 
6
 
 1 d in both
cases) and CD28
 
2
 
/
 
2
 
 groups (15 
 
6
 
 3 and 12 
 
6
 
 1 d, respec-
tively; data not shown). CTLA4-Ig binds to B7 family
members, and has been shown to prolong allograft survival
in other model systems (17). As shown in Fig. 2, significant
prolongation of cardiac allograft survival was achieved by
CTLA4-Ig treatment of wild-type mice (mean graft sur-
vival 
 
5
 
 21 
 
6
 
 4 d,
 
 P 
 
,
 
0.001) or by the combination of
anti-B7 mAbs (graft survival 
 
.
 
24 d for all mice,
 
 P 
 
,
 
0.05).
The difference in allograft survival between wild-type mice
treated with CTLA4-Ig and untreated CD28-deficient ani-
mals was not statistically significant (
 
P
 
 5 
 
0.226). In contrast
to its effect in wild-type animals, treatment with CTLA4-Ig
markedly accelerated graft rejection in CD28-deficient
mice (mean graft survival 
 
5
 
 7 
 
6
 
 1 d,
 
 P 
 
,
 
0.001). Similar
results were obtained in mice treated with a combination
of anti–B7-1 plus anti–B7-2 (8 
 
6
 
 1 d,
 
 P 
 
,
 
0.001).
To confirm that CTLA4 was the B7 receptor responsible
for the inhibition of allograft responses in CD28-deficient
 
mice, animals were treated with a blocking anti-CTLA4
mAb. Previous results have indicated that whole mAb me-
diates the same effects as Fab fragments (2), consistent with
the notion that this mAb is blocking rather than agonistic.
In keeping with the hypothesis that CTLA4 was suppress-
ing T cell responses independent of CD28, treatment with
blocking anti-CTLA4 mAb also accelerated graft rejection
in CD28-deficient mice (8 
 
6
 
 1 d,
 
 P 
 
,
 
0.001; Fig. 3).
 
CTLA4-Ig and Anti-CTLA4 mAb Increase the Cellular In-
filtrate of Allografts in CD28-deficient Mice.
 
Histological ex-
amination of cardiac allografts from untreated mice or from
animals treated with CTLA4-Ig or anti-CTLA4 mAb was
performed on 7-d grafts removed before loss of palpable
heart beat (Fig. 4). Analysis of CD1 allografts in C57BL/6
wild-type and CD28-deficient mice was compatible with
different degrees of acute cellular rejection in all cases. The
heart parenchyma was infiltrated by mononuclear cells, in-
cluding lymphocytes and macrophages. These cellular infil-
trates were associated with a significant destruction of car-
diomyocytes. Allografts removed from untreated wild-type
mice (Fig. 4 
 
C
 
) showed more severe histological signs of
rejection than those from untreated CD28-deficient mice
(Fig. 4 
 
D
 
). In addition, more extensive mononuclear cell
infiltration and cardiomyocyte necrosis were observed in
cardiac allografts harvested from CTLA4-Ig (Fig. 4 
 
E
 
) or
anti-CTLA4–treated (Fig. 4 
 
F
 
) CD28-deficient animals
compared with grafts from untreated CD28-deficient mice,
correlating with the accelerated graft rejection we ob-
served. Signs of acute cellular rejection were absent from
syngeneic grafts, although some fibrosis was observed at
later time points (100 d, Fig. 4 
 
B
 
).
 
CTLA4-Ig and Anti-CTLA4 mAb Treatments Upregulate
Intraallograft IFN-
 
g
 
 Expression in Cardiac Allografts Trans-
planted into CD28-deficient Recipients.
 
Th1-type cytokines
such as IFN-
 
g are associated with acute allograft rejection
(18). To quantitate the pattern of cytokines, RNA was ex-
tracted from cardiac allografts 7 d after transplantation (day
10 is shown in one case for comparison) and from a synge-
neic graft removed at 100 d. Cytokine transcripts present in
the graft at the time of harvest and reflective of infiltrating
mononuclear cells were visualized by RNase protection us-
ing probes for IL-4, IL-6, and IFN-g. Consistent with the
histology results, levels of IFN-g and the monocyte-derived
inflammatory cytokine IL-6 mRNA were upregulated in
Figure 1. Upregulation of CTLA4 in response to alloantigen by wild-
type and CD28-deficient T cells. Splenocytes from wild-type and
CD282/2 mice underwent two rounds of stimulation in vitro with irradi-
ated allogeneic splenocytes, as described in Materials and Methods. 72 h
after the second stimulation, samples were analyzed by flow cytometry.
The histograms represent the fluorescence emitted by wild-type or
CD28-deficient CD41 cells after staining with hamster IgG (thin line) or
anti-CTLA4 mAb (heavy line).
Figure 2. CTLA4-Ig and anti–B7-1 plus anti–B7-2
prolong allograft survival in wild-type mice and accel-
erate graft rejection in CD28-deficient mice. Wild-
type and CD28-deficient mice transplanted with allo-
geneic hearts were either left untreated (open circles; n 5
11 and n 5 12, respectively), or treated with CTLA4-Ig
(filled circles; n 5 5 and n 5 6, respectively) or with a
combination of anti–B7-1 and anti–B7-2 mAbs (filled
squares; n 5 3 and n 5 5, respectively). As additional
controls, transplanted wild-type and CD28-deficient
animals were treated with control human IgG1. Graft
survival curves in IgG1-treated animals were indistin-
guishable from those of untreated mice (data not
shown).202 CTLA4 Blockade Accelerates Allograft Rejection in CD28-deficient Mice
animals from groups in which accelerated rejection was ob-
served (Fig. 5). Hearts from CD28-deficient animals had
decreased levels of IFN-g and IL-6 mRNA compared with
wild-type mice. Treatment of CD28-deficient mice with
CTLA4-Ig or anti-CTLA4 mAb induced an increase in the
levels of both IFN-g and IL-6 mRNA. When hearts from
untreated CD28-deficient mice were harvested at later
time points (day 10), i.e., closer to the time of rejection,
upregulation of the same cytokine transcripts was observed.
IFN-g and IL-6 transcripts could be detected in some con-
trol CD28-deficient mice at day 7 (data not shown), corre-
lating with the fact that some CD282/2 animals reject al-
lografts at earlier time points (see Table 1). No IL-4
mRNA was detected in any of the samples studied (data
not shown). These results suggest that blockade of B7 fam-
ily members induces a decrease in intraallograft Th1-type
responses and global inflammation in wild-type but not in
CD28-deficient mice.
Discussion
Inhibition of the interaction of CTLA4 with B7 family
members induces acceleration of graft rejection in CD28-
deficient mice. Thus, in the absence of CD28, CTLA4 ap-
pears to retain its ability to inhibit T cell responses, indicat-
ing that the function of CTLA4 is not solely to counteract
Figure 3. A blocking anti-
CTLA4 mAb accelerates cardiac
allograft rejection in CD28-defi-
cient mice. CD28-deficient mice
transplanted with allogeneic car-
diac allografts were either not
treated (open circles; n 5 12) or
treated with blocking anti-
CTLA4 mAb (filled circles; n 5 7).
Figure 4. Increased cellular in-
filtrate on allografts of CTLA4-Ig–
and anti-CTLA4–treated CD28-
deficient mice. Cardiac allografts
were removed from untreated
wild-type animals and from un-
treated or CTLA4-Ig– or anti-
CTLA4–treated CD28-deficient
recipients on day 7 after trans-
plantation. As controls, a synge-
neic graft was removed at 100 d,
and an orthotopic heart was
taken from a normal mouse. The
hearts were processed as de-
scribed in Materials and Meth-
ods, and examined using an opti-
cal microscope at a magnification
of 200. KO, Knockout.203 Lin et al. Brief Definitive Report
CD28 signaling. This inhibitory effect of CTLA4 could, in
principle, be achieved through the direct inhibition of TCR
signaling or, alternatively, by antagonizing a compensatory
costimulatory receptor on CD28-deficient T cells.
Although the role of CD28 as a positive costimulatory
receptor is well established, CTLA4 appears to be a nega-
tive regulator of T cell responses. Recently, the negative
role of CTLA4 on T cell activation has become controver-
sial. Indeed, contradictory reports have been published, in-
dicating either that CTLA4 downregulates T cell responses
(10, 19) or that CTLA4 can act as a weak costimulatory
molecule in some systems (20). However, if a positive role
of CTLA4 was masked under normal circumstances by the
more potent costimulatory molecule CD28, one would
have expected blockade of CTLA4 to induce prolongation
of allograft survival in our model of cardiac transplantation
in CD28-deficient mice. In contrast, whether CTLA4 liga-
tion was prevented by blocking B7 family members on the
APC side with anti–B7-1 plus anti–B7-2 mAbs or CTLA4-
Ig, or by blocking CTLA4 directly on the T cell side with
anti-CTLA4 mAb, the outcome was acceleration of graft
rejection, further supporting an inhibitory role for CTLA4
on T cell responses. It is of interest that blockade of ligation
of both CD28 and CTLA4 by CTLA4-Ig or by anti–B7-1
plus anti–B7-2 mAbs led to different outcomes in wild-
type mice compared with CD28-deficient mice. Treat-
ment in wild-type mice resulted in prolonged allograft sur-
vival comparable to that of untreated CD28-deficient
recipients, whereas treatment in CD28-deficient animals
led to rapid graft rejection similar to that of untreated wild-
type mice. These results suggest a dominant role of CD28
in wild-type T cells, whereas a distinctive inhibitory role of
CTLA4 is revealed in CD28-deficient T cells.
Little is known about how CTLA4 inhibits T cell re-
sponses. Because CTLA4 has a higher affinity for B7 family
members than CD28, it has been hypothesized that down-
regulation of T cell activation could be mediated through
competition for ligand and decreased CD28 costimulation.
Recent reports have suggested an additional signaling role
for CTLA4. First, the cytoplasmic tail of CTLA4 has been
found to associate with the intracellular enzymes PI3-kinase
(13) and protein tyrosine phosphatase 2 (SHP-2) (21). Sec-
ond, CTLA4 cross-linking has been shown to decrease the
activity of extracellular signal–regulated kinase and jun
NH2-terminal kinase induced by TCR stimulation of pre-
activated T cells in vitro (22).
It has been reported recently that in an alternative mouse
cardiac allograft model, CTLA4-Ig treatment did not have
any detectable effect in CD28-deficient mice compared
with animals receiving control IgG (23). The reasons for
the different findings in the two models remain unclear.
However, Pearson and co-workers positioned the cardiac
allografts intraperitoneally rather than in a cervical location.
It is conceivable that peritoneal macrophages may contrib-
ute to rejection regardless of CTLA4 expression on T cells
in this setting. In addition, it is possible that the H-2k into
H-2b combination used by Pearson et al. is less potent at
inducing CTLA4 expression than is H-2q into H-2b.
The levels of intragraft cytokine transcripts correlated
with the numbers of mononuclear cells infiltrating the al-
lografts. Increased levels of the proinflammatory cytokines
IFN-g and IL-6 were observed in grafts from CD28-defi-
cient animals treated with blocking anti-CTLA4 mAb.
However, detectable levels of IL-4 were not observed in
any hearts (data not shown), indicating absence of infiltrat-
ing Th2-type cells. This argues for the preferential genera-
tion of Th1-type cytokines in this model, as it appears that
anti-CTLA4 mAb can augment cytokine production by
both Th1- and Th2-type cells (references 4 and 6, and
Alegre, M.L., H. Shiels, C.B. Thompson, and T.F. Gajew-
ski, manuscript submitted for publication). Therefore, one
would expect anti-CTLA4 mAb also to increase Th2-type
cytokine production, if Th2-type cells were generated after
allograft challenge.
Our findings provide evidence for a role of CTLA4 in-
dependent of that of CD28 in vivo. The data strongly sup-
port the hypothesis that the function of CTLA4 as a negative
regulator extends beyond its potential ability to inhibit ligand
binding to CD28, and can be exerted in the absence of CD28.
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Figure 5. CTLA4-Ig and anti-
CTLA4 mAb induce upregulation
of IFN-g transcripts in allografts
from CD28-deficient recipients.
Cardiac allografts removed 7 d
(10 d in one case) after transplan-
tation. As controls, a syngeneic
graft was removed at 100 d, and
an orthotopic heart was taken
from a normal mouse. Samples
were homogenized, RNA was
extracted, and levels of cytokine
transcripts were determined by
RNase protection.204 CTLA4 Blockade Accelerates Allograft Rejection in CD28-deficient Mice
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